NCT06787612 2026-04-08
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
Phase 2 Recruiting
Clinical Trials
3 trialsNCT06014528 2025-04-30
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 2 Recruiting
NCT05536102 2023-03-09
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting